Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2813091

Concept 2022-01-01 to
2022-12-31
As at
2022-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations
3 456 EUR
4 948 EUR
Income taxes paid (refund), classified as operating activities
- EUR
- EUR
Cash flows from (used in) operating activities
3 359 EUR
6 692 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
- EUR
3,000 EUR
Purchase of property, plant and equipment, classified as investing activities
165,000 EUR
166,000 EUR
Proceeds from sales of intangible assets, classified as investing activities
- EUR
- EUR
Purchase of intangible assets, classified as investing activities
10,000 EUR
- EUR
Cash flows from (used in) investing activities
175,000 EUR
1 338 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
- EUR
4 056 EUR
Repayments of borrowings, classified as financing activities
236,000 EUR
19,000 EUR
Cash flows from (used in) financing activities
194,000 EUR
3 972 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
- EUR
- EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
3 728 EUR
1 382 EUR
Cash and cash equivalents
4 046 EUR
7 935 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.